Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis

James Walter; Lorraine B. Ware; Michael A. Matthay

doi:10.1016/S2213-2600(14)70217-6

Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis

James Walter, Lorraine B. Ware, Michael A. Matthay^*

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Review article › peer-review

112 Scopus citations

Abstract

Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.

Original language	English (US)
Pages (from-to)	1016-1026
Number of pages	11
Journal	The Lancet Respiratory Medicine
Volume	2
Issue number	12
DOIs	https://doi.org/10.1016/S2213-2600(14)70217-6
State	Published - Dec 1 2014

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/S2213-2600(14)70217-6

Fingerprint Dive into the research topics of 'Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis'. Together they form a unique fingerprint.

Cite this

@article{842d2c4cb6784b74a793b2d755426087,

title = "Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis",

abstract = "Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.",

author = "James Walter and Ware, {Lorraine B.} and Matthay, {Michael A.}",

note = "Funding Information: MAM reports grants from the National Heart, Lung, and Blood Institute, GlaxoSmithKline, and the National Institute of Allergy and Infectious Diseases, as well as consulting work with Cerus and Roche-Genetec (Chair of Data and Safety Monitoring Board). The other authors declare no competing interests. Funding Information: The authors thank Diana Lim for her excellent work in preparing the figure . MAM was supported in part by NHLBI R37HL51856 and R01HL51854.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/S2213-2600(14)70217-6",

language = "English (US)",

volume = "2",

pages = "1016--1026",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Mesenchymal stem cells

T2 - Mechanisms of potential therapeutic benefit in ARDS and sepsis

AU - Walter, James

AU - Ware, Lorraine B.

AU - Matthay, Michael A.

N1 - Funding Information: MAM reports grants from the National Heart, Lung, and Blood Institute, GlaxoSmithKline, and the National Institute of Allergy and Infectious Diseases, as well as consulting work with Cerus and Roche-Genetec (Chair of Data and Safety Monitoring Board). The other authors declare no competing interests. Funding Information: The authors thank Diana Lim for her excellent work in preparing the figure . MAM was supported in part by NHLBI R37HL51856 and R01HL51854.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.

AB - Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.

UR - http://www.scopus.com/inward/record.url?scp=84919859861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919859861&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(14)70217-6

DO - 10.1016/S2213-2600(14)70217-6

M3 - Review article

C2 - 25465643

AN - SCOPUS:84919859861

VL - 2

SP - 1016

EP - 1026

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 12

ER -